Scarica l'app Stockscreener
13.15
0.19%
-0.025
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$13.18
Aprire:
$13.11
Volume 24 ore:
2.03M
Relative Volume:
0.68
Capitalizzazione di mercato:
$1.87B
Reddito:
-
Utile/perdita netta:
$-412.89M
Rapporto P/E:
-3.4067
EPS:
-3.86
Flusso di cassa netto:
$-361.93M
1 W Prestazione:
-7.52%
1M Prestazione:
+13.17%
6M Prestazione:
+6.39%
1 anno Prestazione:
-60.24%
Intervallo 1D:
$13.07
$13.68
Intervallo di 1 settimana:
$12.62
$14.22
Portata 52W:
$6.36
$37.08
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
13.15 | 1.89B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
59,673 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Voleon Capital Management LP - MarketBeat
Graham Capital Management L.P. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 2,640 Shares - MarketBeat
Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $34.07 - MarketBeat
Exome Asset Management LLC Acquires Shares of 258,391 Dyne Therapeutics, Inc. $DYN - MarketBeat
Invesco Ltd. Has $693,000 Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating - Yahoo Finance
Dyne therapeutics CMO Kerr sells shares worth $59k By Investing.com - Investing.com Canada
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Trexquant Investment LP - MarketBeat
224,176 Shares in Dyne Therapeutics, Inc. $DYN Bought by PDT Partners LLC - MarketBeat
RA Capital Management L.P. Buys 3,333,248 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Palo Alto Investors LP Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Will Dyne Therapeutics Inc. outperform the market2025 Price Momentum & Free Growth Oriented Trading Recommendations - Newser
Trend analysis for Dyne Therapeutics Inc. this week2025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
Market reaction to Dyne Therapeutics Inc.’s recent newsInsider Selling & Technical Entry and Exit Tips - Newser
ADAR1 Capital Management LLC Buys Shares of 30,099 Dyne Therapeutics, Inc. $DYN - MarketBeat
Rafferty Asset Management LLC Sells 20,129 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. benefit from deglobalizationJuly 2025 Catalysts & Low Drawdown Momentum Ideas - خودرو بانک
Can Dyne Therapeutics Inc. be recession proofJuly 2025 Pullbacks & Intraday High Probability Alerts - خودرو بانک
Will Dyne Therapeutics Inc. stock recover after recent dropGap Down & Free Real-Time Volume Trigger Notifications - Newser
Dyne Therapeutics, Inc. $DYN Shares Bought by Armistice Capital LLC - MarketBeat
Chart based analysis of Dyne Therapeutics Inc. trendsMarket Movement Recap & Reliable Breakout Forecasts - Newser
Will Dyne Therapeutics Inc. benefit from government policyWeekly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Can Dyne Therapeutics Inc. navigate macro headwindsCPI Data & AI Based Buy and Sell Signals - خودرو بانک
What is the dividend yield of Dyne Therapeutics Inc.2025 Major Catalysts & Accurate Trade Setup Notifications - خودرو بانک
Is Dyne Therapeutics Inc. meeting your algorithmic filter criteria2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Dyne Therapeutics Inc. stock prediction for this week2025 Price Targets & AI Enhanced Trading Signals - Newser
Russell Investments Group Ltd. Has $710,000 Stock Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
How to use Fibonacci retracement on Dyne Therapeutics Inc.Earnings Overview Summary & Weekly Sector Rotation Insights - Newser
Will Dyne Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Risk Controlled Daily Plans - Newser
Custom watchlist performance reports with Dyne Therapeutics Inc.Dollar Strength & Low Drawdown Momentum Ideas - Newser
Is it time to cut losses on Dyne Therapeutics Inc.2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser
Intraday pattern recognizer results for Dyne Therapeutics Inc.July 2025 Short Interest & Weekly Breakout Watchlists - Newser
Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT - MSN
Can Dyne Therapeutics Inc. expand its profit marginsJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - خودرو بانک
Live market analysis of Dyne Therapeutics Inc.Weekly Trade Review & Risk Managed Investment Entry Signals - Newser
Key metrics from Dyne Therapeutics Inc.’s quarterly dataJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Newser
Should you hold or exit Dyne Therapeutics Inc. nowWeekly Stock Summary & Short-Term Trading Opportunity Alerts - Newser
Tick level data insight on Dyne Therapeutics Inc. volatilityLayoff News & Free Technical Confirmation Trade Alerts - Newser
Dyne Therapeutics, Inc. $DYN Shares Purchased by Siren L.L.C. - MarketBeat
Will Dyne Therapeutics Inc. continue its uptrendMarket Sentiment Report & High Accuracy Swing Entry Alerts - Newser
Pattern recognition hints at Dyne Therapeutics Inc. upsideQuarterly Market Summary & Expert Approved Momentum Ideas - Newser
Using fundamentals and technicals on Dyne Therapeutics Inc.July 2025 Sector Moves & Growth Focused Stock Reports - Newser
Is Dyne Therapeutics Inc. forming a double bottomProfit Target & Fast Momentum Stock Entry Tips - beatles.ru
Is Dyne Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - Newser
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '25 |
Sale |
13.27 |
894 |
11,863 |
95,017 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 05 '25 |
Sale |
13.41 |
144 |
1,931 |
94,873 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '25 |
Sale |
13.27 |
3,552 |
47,135 |
89,263 |
| Kerr Douglas | Chief Medical Officer |
Sep 05 '25 |
Sale |
13.41 |
873 |
11,707 |
88,390 |
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):